Efforts to reduce delays in diagnosis and treatment of cardiorenal and metabolic diseases—such as obesity, metabolic syndrome, prediabetes, diabetes, and heart failure—require a shift toward earlier, more intensive...
Mayra Cantazaro,
DNP, FNP-BC, BC-ADM, CDCES
Family Nurse Practitioner, Valley Diabetes and Endocrinology Comprehensive Center
Statins and PCSK9 Inhibitors Tied to Higher Microvascular Risk in Diabetes
This Mendelian randomization (MR) study investigated whether three classes of cholesterol-lowering drugs—HMGCR inhibitors (eg, statins), PCSK9 inhibitors, and NPC1L1 inhibitors—causally...
Empagliflozin Lowers Cardiovascular Death and Mortality in High-Risk Patients With Type 2 Diabetes
Researchers of a large, randomized trial evaluated the cardiovascular effects of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients...
